Pharma & Biotech
You will receive alerts when there are new announcements on Imugene Ltd
Only registered members can use this feature.
Imugene Ltd (ASX:IMU) is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors.
The company is well-funded to deliver on commercial and clinical milestones including the development of CF33, PD1-Vaxx and HER-Vaxx treatments.
© Proactive Investors 2021.
Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.